Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Daily Top 10 COVID-19 papers


  Liver Diseases

  Free Subscription


4 Am J Gastroenterol
3 Am J Pathol
2 Ann Intern Med
5 Anticancer Res
1 Biochem Biophys Res Commun
2 BMC Cancer
1 BMC Gastroenterol
1 Br J Surg
1 Cancer Res
3 Clin Res Hepatol Gastroenterol
3 Dig Dis Sci
1 Gastroenterology
4 Gut
1 Hepatology
1 Indian J Gastroenterol
3 J Comput Assist Tomogr
1 J Gastroenterol Hepatol
9 J Hepatol
1 J Pediatr
16 PLoS One
7 Proc Natl Acad Sci U S A
1 Radiology
1 Semin Liver Dis
3 Transplant Proc
5 Transplantation

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Am J Gastroenterol

  1. ALLEN AM, Therneau TM, Mara KC, Larson JJ, et al
    Women With Nonalcoholic Fatty Liver Disease Lose Protection Against Cardiovascular Disease: A Longitudinal Cohort Study.
    Am J Gastroenterol. 2019;114:1764-1771.
    PubMed         Abstract available

  2. HARRIS R, Card TR, Delahooke T, Aithal GP, et al
    Obesity Is the Most Common Risk Factor for Chronic Liver Disease: Results From a Risk Stratification Pathway Using Transient Elastography.
    Am J Gastroenterol. 2019;114:1744-1752.
    PubMed         Abstract available

  3. BAJAJ JS, Lauridsen M, Tapper EB, Duarte-Rojo A, et al
    Important Unresolved Questions in the Management of Hepatic Encephalopathy: An ISHEN Consensus.
    Am J Gastroenterol. 2020 Mar 30. doi: 10.14309/ajg.0000000000000603.
    PubMed         Abstract available

  4. KAPILA N, Dorsey YC, Shah J, King L, et al
    Transjugular Intrahepatic Portosystemic Shunt for a Challenging Pregnancy.
    Am J Gastroenterol. 2020 Mar 26. doi: 10.14309/ajg.0000000000000602.

    Am J Pathol

  5. KRISHNAN A, Katsumi T, Guicciardi ME, Azad AI, et al
    TRAIL Receptor Deficiency Promotes the Ductular Reaction, Macrophage Accumulation and Hepatic Fibrosis in the Mdr2(-/-) Mouse.
    Am J Pathol. 2020 Mar 30. pii: S0002-9440(20)30135.
    PubMed         Abstract available

  6. ROTH K, Strickland J, Joshi N, Deng M, et al
    Dichotomous Role of Plasmin in Regulation of Macrophage Function after Acetaminophen Overdose.
    Am J Pathol. 2019;189:1986-2001.
    PubMed         Abstract available

  7. YAN S, Zhou J, Chen X, Dong Z, et al
    Diverse Consequences in Liver Injury in Mice with Different Autophagy Functional Status Treated with Alcohol.
    Am J Pathol. 2019;189:1744-1762.
    PubMed         Abstract available

    Ann Intern Med

  8. LIBMAN H, Jiang ZG, Tapper EB, Reynolds EE, et al
    How Would You Manage This Patient With Nonalcoholic Fatty Liver Disease?
    Ann Intern Med. 2019;171:862.

    How Would You Manage This Patient With Nonalcoholic Fatty Liver Disease?
    Ann Intern Med. 2019;171:861-862.

    Anticancer Res

  10. JELSKI W, Piechota J, Orywal K, Mroczko B, et al
    The Alterations in Alcohol Dehydrogenase Activity in the Sera of Women With Intrahepatic Cholestasis of Pregnancy.
    Anticancer Res. 2020;40:1997-2001.
    PubMed         Abstract available

  11. ZARLING L, Emamekhoo H, Bhutani G, Ziemlewicz T, et al
    Polycystic Liver Disease in a Patient With Metastatic Renal Cell Carcinoma: A Case Report.
    Anticancer Res. 2020;40:1527-1534.
    PubMed         Abstract available

  12. KUZUYA T, Ishigami M, Ito T, Ishizu Y, et al
    Sorafenib vs. Lenvatinib as First-line Therapy for Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis.
    Anticancer Res. 2020;40:2283-2290.
    PubMed         Abstract available

  13. LIU LI, Ahn E, Studeman K, Campbell K, et al
    Primary Hepatic Carcinosarcoma Composed of Hepatocellular Carcinoma, Cholangiocarcinoma, Osteosarcoma and Rhabdomyosarcoma With Poor Prognosis.
    Anticancer Res. 2020;40:2225-2229.
    PubMed         Abstract available

  14. KUZUYA T, Ishigami M, Ito T, Ishizu Y, et al
    Initial Experience of Ramucirumab Treatment After Lenvatinib Failure for Patients With Advanced Hepatocellular Carcinoma.
    Anticancer Res. 2020;40:2089-2093.
    PubMed         Abstract available

    Biochem Biophys Res Commun

  15. LI YN, Su Y
    Remdesivir attenuates high fat diet (HFD)-induced NAFLD by regulating hepatocyte dyslipidemia and inflammation via the suppression of STING.
    Biochem Biophys Res Commun. 2020 Mar 26. pii: S0006-291X(20)30513.
    PubMed         Abstract available

    BMC Cancer

  16. SHAO Z, Jiao B, Yu J, Liu H, et al
    Primary low grade myxofibrosarcoma of the liver with benign presentation but malignant outcome: a case report.
    BMC Cancer. 2019;19:1098.
    PubMed         Abstract available

  17. ZHANG Z, Zhou Y, Hu K, Wang D, et al
    Perineural invasion as a prognostic factor for intrahepatic cholangiocarcinoma after curative resection and a potential indication for postoperative chemotherapy: a retrospective cohort study.
    BMC Cancer. 2020;20:270.
    PubMed         Abstract available

    BMC Gastroenterol

  18. ZHANG XM, Tong Y, Li Q, He Q, et al
    Diffused hepatic angiosarcoma with Kasabach-Merritt syndrome-case report and literature review.
    BMC Gastroenterol. 2020;20:80.
    PubMed         Abstract available

    Br J Surg

  19. WALLACE D, Cowling TE, Walker K, Suddle A, et al
    Liver transplantation outcomes after transarterial chemotherapy for hepatocellular carcinoma.
    Br J Surg. 2020 Mar 28. doi: 10.1002/bjs.11559.
    PubMed         Abstract available

    Cancer Res

  20. ZHU H, Yan F, Yuan T, Qian M, et al
    USP10 Promotes Proliferation of Hepatocellular Carcinoma by Deubiquitinating and Stabilizing YAP/TAZ.
    Cancer Res. 2020 Mar 26. pii: 0008-5472.CAN-19-2388.
    PubMed         Abstract available

    Clin Res Hepatol Gastroenterol

  21. LEBRAY P, Varnous S
    Combined heart and liver transplantation: State of knowledge and outlooks.
    Clin Res Hepatol Gastroenterol. 2019 Jan 8. pii: S2210-7401(18)30173.
    PubMed         Abstract available

  22. SCHIELKE A, Scatton O, Boelle PY, Perdigao F, et al
    Ischemic-type biliary lesions: A leading indication of liver retransplantation with excellent results.
    Clin Res Hepatol Gastroenterol. 2019;43:131-139.
    PubMed         Abstract available

  23. MURATORI P, Lenzi M, Muratori L
    Diagnosis of primary biliary cholangitis in a "teen" male patient.
    Clin Res Hepatol Gastroenterol. 2019;43:e20-e21.

    Dig Dis Sci

  24. WANG C, Luo J, Chen Z, Ye M, et al
    MiR-375 Impairs the Invasive Capabilities of Hepatoma Cells by Targeting HIF1alpha Under Hypoxia.
    Dig Dis Sci. 2020 Mar 25. pii: 10.1007/s10620-020-06202.
    PubMed         Abstract available

  25. ZORI A, Villanueva F, Hatamleh D, Ismael M, et al
    Favorable Survival with Non-curative Treatments for Patients with Early-Stage Hepatocellular Carcinoma After Liver Transplant Denial.
    Dig Dis Sci. 2020 Mar 26. pii: 10.1007/s10620-020-06201.
    PubMed         Abstract available

  26. TURKSEVEN S, Bolognesi M, Di Pascoli M
    Contribution of Splenic Resistance Arteries to Splanchnic Blood Overflow in Cirrhosis.
    Dig Dis Sci. 2020 Apr 2. pii: 10.1007/s10620-020-06233.
    PubMed         Abstract available


  27. EL-SERAG HB, Kanwal F, Feng Z, Marrero JA, et al
    Risk Factors for Cirrhosis in Contemporary Hepatology Practices-Findings from Texas Hepatocellular Carcinoma Consortium Cohort.
    Gastroenterology. 2020 Mar 29. pii: S0016-5085(20)30403.


  28. JUHLING F, Hamdane N, Crouchet E, Li S, et al
    Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma.
    Gut. 2020 Mar 26. pii: gutjnl-2019-318918. doi: 10.1136/gutjnl-2019-318918.
    PubMed         Abstract available

  29. HUTCHINSON SJ, Valerio H, McDonald SA, Yeung A, et al
    Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: a national record-linkage study.
    Gut. 2020 Mar 26. pii: gutjnl-2019-320007. doi: 10.1136/gutjnl-2019-320007.
    PubMed         Abstract available

  30. SU F, Ioannou GN, Berry K
    No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir.
    Gut. 2020 Mar 30. pii: gutjnl-2019-319867. doi: 10.1136/gutjnl-2019-319867.
    PubMed         Abstract available

  31. MONTEIRO S, Grandt J, Uschner FE, Kimer N, et al
    Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation.
    Gut. 2020 Apr 2. pii: gutjnl-2019-320170. doi: 10.1136/gutjnl-2019-320170.
    PubMed         Abstract available


  32. LIU Y, Yang W, VoPham T, Ma Y, et al
    Plant-based and animal-based low-carbohydrate diets and risk of hepatocellular carcinoma among US men and women.
    Hepatology. 2020 Mar 29. doi: 10.1002/hep.31251.
    PubMed         Abstract available

    Indian J Gastroenterol

  33. LAZAR MV, Eapen M, Nair HR, Siyad I, et al
    Correlation between insulin resistance and liver histology in patients with nonalcoholic steatohepatitis with and without obesity.
    Indian J Gastroenterol. 2020 Mar 28. pii: 10.1007/s12664-020-01024.
    PubMed         Abstract available

    J Comput Assist Tomogr

  34. HAN P, Zhou Z, Wang R, Wang H, et al
    Quantitative Assessment of Extracellular Volume in Doxorubicin-Induced Liver Injury in Beagle Models by Equilibrium Computed Tomography.
    J Comput Assist Tomogr. 2020;44:204-208.
    PubMed         Abstract available

  35. ABDEL RAZEK AAK, El-Serougy LG, Saleh GA, Shabana W, et al
    Liver Imaging Reporting and Data System Version 2018: What Radiologists Need to Know.
    J Comput Assist Tomogr. 2020;44:168-177.
    PubMed         Abstract available

  36. PUTTAGUNTA S, van der Pol CB, Ferri M, Sy Wat J, et al
    Diagnostic Accuracy of Single-Phase Computed Tomography Texture Analysis for Prediction of LI-RADS v2018 Category.
    J Comput Assist Tomogr. 2020;44:188-192.
    PubMed         Abstract available

    J Gastroenterol Hepatol

  37. KIM JH, Kang SH, Lee M, Choi HS, et al
    Improved Detection of Hepatocellular Carcinoma by Dynamic CT in Cirrhotic Patients With Chronic Hepatitis B: A Multi-Center Study.
    J Gastroenterol Hepatol. 2020 Mar 28. doi: 10.1111/jgh.15046.
    PubMed         Abstract available

    J Hepatol

  38. KHAN SA, Clements O, Kim JU, Eliahoo J, et al
    Reply to: 'Letter regarding [Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis]'.
    J Hepatol. 2020 Mar 23. pii: S0168-8278(20)30128.

  39. PARK HJ, Jang HY, Kim SY
    Reply to: "Non-enhanced magnetic resonance as a surveillance tool for hepatocellular carcinoma: Many unresolved issues".
    J Hepatol. 2020 Mar 26. pii: S0168-8278(20)30162.

  40. PAPATHEODORIDIS GV, Lampertico P
    Reply to: "Clinical relevance of dynamic risk assessment for developing hepatocellular carcinoma during prolonged antiviral therapy".
    J Hepatol. 2020 Mar 27. pii: S0168-8278(20)30173.

  41. NEWSOME PN, Palmer M, Freilich B, Sheikh MY, et al
    Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study.
    J Hepatol. 2020 Mar 28. pii: S0168-8278(20)30186.
    PubMed         Abstract available

  42. CARRILLO-REIXACH J, Torrens L, Simon-Coma M, Royo L, et al
    Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications.
    J Hepatol. 2020 Mar 30. pii: S0168-8278(20)30187.
    PubMed         Abstract available

  43. BERNSMEIER C, van der Merwe S, Perianin A
    The innate immune cells in cirrhosis.
    J Hepatol. 2020 Mar 30. pii: S0168-8278(20)30189.
    PubMed         Abstract available

  44. LAI JC, Dodge JL, Kappus MR, Dunn MA, et al
    Changes in frailty are associated with waitlist mortality in patients with cirrhosis.
    J Hepatol. 2020 Mar 30. pii: S0168-8278(20)30191.
    PubMed         Abstract available

  45. VERNA EC, Morelli G, Terrault NA, Lok AS, et al
    DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.
    J Hepatol. 2020 Mar 31. pii: S0168-8278(20)30193.
    PubMed         Abstract available

  46. SANGIOVANNI A, Alimenti E, Gattai R, Filomia R, et al
    Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis.
    J Hepatol. 2020 Mar 31. pii: S0168-8278(20)30192.
    PubMed         Abstract available

    J Pediatr

  47. MOUZAKI M, Trout AT
    Virtual Reality: New Insights Regarding the Prevalence of Nonalcoholic Fatty Liver Disease in Children and Adolescents with Obesity Using Magnetic Resonance Imaging.
    J Pediatr. 2019;207:8-10.

    PLoS One

  48. ZHONG GC, Liu S, Wu YL, Xia M, et al
    ABO blood group and risk of newly diagnosed nonalcoholic fatty liver disease: A case-control study in Han Chinese population.
    PLoS One. 2019;14:e0225792.
    PubMed         Abstract available

  49. SU RC, Lad A, Breidenbach JD, Blomquist TM, et al
    Hyperglycemia induces key genetic and phenotypic changes in human liver epithelial HepG2 cells which parallel the Leprdb/J mouse model of non-alcoholic fatty liver disease (NAFLD).
    PLoS One. 2019;14:e0225604.
    PubMed         Abstract available

  50. ABBASS MA, Ahmad SA, Mahalingam N, Krothapalli KS, et al
    In vivo ultrasound thermal ablation control using echo decorrelation imaging in rabbit liver and VX2 tumor.
    PLoS One. 2019;14:e0226001.
    PubMed         Abstract available

  51. SCOTT C, Stokes R, Cha KM, Clouston A, et al
    Myeloid cell deletion of Aryl hydrocarbon Receptor Nuclear Translocator (ARNT) induces non-alcoholic steatohepatitis.
    PLoS One. 2019;14:e0225332.
    PubMed         Abstract available

  52. WELDEAREGAY KT, Gebrekidan MG, Gezahegne AA
    Health impact of hepatic-venous-occlusive disease in a small town in Ethiopia-Case study from Tahtay koraro district in Tigray region, 2017.
    PLoS One. 2019;14:e0224659.
    PubMed         Abstract available

  53. SENDRA L, Herrero MJ, Montalva EM, Noguera I, et al
    Efficacy of interleukin 10 gene hydrofection in pig liver vascular isolated 'in vivo' by surgical procedure with interest in liver transplantation.
    PLoS One. 2019;14:e0224568.
    PubMed         Abstract available

  54. YANG S, Kwak S, Lee JH, Kang S, et al
    Nonalcoholic fatty liver disease is an early predictor of metabolic diseases in a metabolically healthy population.
    PLoS One. 2019;14:e0224626.
    PubMed         Abstract available

  55. BUCHER JN, Koenig M, Schoenberg MB, Crispin A, et al
    Liver transplantation in patients with a history of migration-A German single center comparative analysis.
    PLoS One. 2019;14:e0224116.
    PubMed         Abstract available

  56. BAJAJ JS, Fan S, Thacker LR, Fagan A, et al
    Serum and urinary metabolomics and outcomes in cirrhosis.
    PLoS One. 2019;14:e0223061.
    PubMed         Abstract available

  57. ISHIKAWA T, Sasaki R, Nishimura T, Aibe Y, et al
    A novel therapeutic strategy for esophageal varices using endoscopic treatment combined with splenic artery embolization according to the Child-Pugh classification.
    PLoS One. 2019;14:e0223153.
    PubMed         Abstract available

  58. LIU Y, Liu X, Wang Y, Yi C, et al
    Protective effect of lactobacillus plantarum on alcoholic liver injury and regulating of keap-Nrf2-ARE signaling pathway in zebrafish larvae.
    PLoS One. 2019;14:e0222339.
    PubMed         Abstract available

  59. LEVICK C, Phillips-Hughes J, Collier J, Banerjee R, et al
    Non-invasive assessment of portal hypertension by multi-parametric magnetic resonance imaging of the spleen: A proof of concept study.
    PLoS One. 2019;14:e0221066.
    PubMed         Abstract available

  60. ERKAN B, Meier J, Clark TJ, Kaplan J, et al
    Non-invasive diagnostic criteria of hepatocellular carcinoma: Comparison of diagnostic accuracy of updated LI-RADS with clinical practice guidelines of OPTN-UNOS, AASLD, NCCN, EASL-EORTC, and KLSCG-NCC.
    PLoS One. 2019;14:e0226291.
    PubMed         Abstract available

  61. SUDJARITRUK T, Bunupuradah T, Aurpibul L, Kosalaraksa P, et al
    Nonalcoholic fatty liver disease and hepatic fibrosis among perinatally HIV-monoinfected Asian adolescents receiving antiretroviral therapy.
    PLoS One. 2019;14:e0226375.
    PubMed         Abstract available

  62. HOWELL AK, McCann CM, Wickstead F, Williams DJL, et al
    Co-infection of cattle with Fasciola hepatica or F. gigantica and Mycobacterium bovis: A systematic review.
    PLoS One. 2019;14:e0226300.
    PubMed         Abstract available

  63. KLEIN WM, Sonnemans LJP, Franckenberg S, Fliss B, et al
    Pseudolesion in the right parafissural liver parenchyma on CT: The base is found in embryology and collagen content.
    PLoS One. 2020;15:e0221544.
    PubMed         Abstract available

    Proc Natl Acad Sci U S A

  64. TRUONG B, Allegri G, Liu XB, Burke KE, et al
    Lipid nanoparticle-targeted mRNA therapy as a treatment for the inherited metabolic liver disorder arginase deficiency.
    Proc Natl Acad Sci U S A. 2019;116:21150-21159.
    PubMed         Abstract available

  65. LIU K, Theusch E, Zhou Y, Ashuach T, et al
    GeneFishing to reconstruct context specific portraits of biological processes.
    Proc Natl Acad Sci U S A. 2019;116:18943-18950.
    PubMed         Abstract available

  66. WANG L, Mazagova M, Pan C, Yang S, et al
    YIPF6 controls sorting of FGF21 into COPII vesicles and promotes obesity.
    Proc Natl Acad Sci U S A. 2019 Jul 9. pii: 1904360116.
    PubMed         Abstract available

  67. KINGSTON BR, Syed AM, Ngai J, Sindhwani S, et al
    Assessing micrometastases as a target for nanoparticles using 3D microscopy and machine learning.
    Proc Natl Acad Sci U S A. 2019;116:14937-14946.
    PubMed         Abstract available

  68. TORRES C, Mancinelli G, Cordoba-Chacon J, Viswakarma N, et al
    p110gamma deficiency protects against pancreatic carcinogenesis yet predisposes to diet-induced hepatotoxicity.
    Proc Natl Acad Sci U S A. 2019 Jul 2. pii: 1813012116.
    PubMed         Abstract available

  69. HUA G, Zein N, Paulen L, Chambon P, et al
    The glucocorticoid receptor agonistic modulators CpdX and CpdX-D3 do not generate the debilitating effects of synthetic glucocorticoids.
    Proc Natl Acad Sci U S A. 2019;116:14200-14209.
    PubMed         Abstract available

  70. MIYAUCHI T, Uchida Y, Kadono K, Hirao H, et al
    Up-regulation of FOXO1 and reduced inflammation by beta-hydroxybutyric acid are essential diet restriction benefits against liver injury.
    Proc Natl Acad Sci U S A. 2019;116:13533-13542.
    PubMed         Abstract available


  71. MULE S, Galletto Pregliasco A, Tenenhaus A, Kharrat R, et al
    Multiphase Liver MRI for Identifying the Macrotrabecular-Massive Subtype of Hepatocellular Carcinoma.
    Radiology. 2020 Mar 31:192230. doi: 10.1148/radiol.2020192230.
    PubMed         Abstract available

    Semin Liver Dis

  72. MATSUDA M, Seki E
    Hepatic Stellate Cell-Macrophage Crosstalk in Liver Fibrosis and Carcinogenesis.
    Semin Liver Dis. 2020 Apr 2. doi: 10.1055/s-0040-1708876.
    PubMed         Abstract available

    Transplant Proc

  73. RIAL X, Lopez-Monclus J, Lucena JL, Chaparro MD, et al
    Hepatic Epithelioid Hemangioendothelioma as a Rare Indication for Liver Transplantation.
    Transplant Proc. 2020 Mar 30. pii: S0041-1345(19)31831.
    PubMed         Abstract available

  74. CIECIURA T, Urbanowicz A, Foroncewicz B, Hryniewiecka E, et al
    Hepatocellular Carcinoma Is a Negative Predictor of Sustained Viral Response in Liver Transplant Recipients With Hepatitis C Treated With Direct-Acting Antivirals.
    Transplant Proc. 2020 Mar 30. pii: S0041-1345(19)31659.
    PubMed         Abstract available

  75. KRASNODEBSKI M, Grat M, Morawski M, Wierzchowski M, et al
    Hepatic Epithelioid Hemangioendothelioma: A Rare Disease With Favorable Outcomes After Liver Transplantation.
    Transplant Proc. 2020 Mar 23. pii: S0041-1345(20)30121.
    PubMed         Abstract available


  76. RHU J, Kim JM, Choi GS, Kwon CHD, et al
    The Authors' Reply: Anatomical and Extra-Anatomical Hepatic Artery Reconstruction During Living Donor Liver Transplantation: Is It Reasonable to Classify This Way?
    Transplantation. 2020;104:e112-e113.

  77. HIBI T, Rela M, Eason J, Line PD, et al
    Liver Transplantation for Colorectal and Neuroendocrine Liver Metastases and Hepatoblastoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference.
    Transplantation. 2020 Mar 23. doi: 10.1097/TP.0000000000003118.
    PubMed         Abstract available

  78. MEHTA N, Bhangui P, Yao FY, Mazzaferro V, et al
    Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference.
    Transplantation. 2020 Mar 23. doi: 10.1097/TP.0000000000003174.

  79. SAPISOCHIN G, Javle M, Lerut J, Ohtsuka M, et al
    Liver Transplantation for Cholangiocarcinoma and Mixed Hepatocellular-cholangiocarcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference.
    Transplantation. 2020 Mar 23. doi: 10.1097/TP.0000000000003212.
    PubMed         Abstract available

  80. BERENGUER M, Burra P, Ghobrial M, Hibi T, et al
    Posttransplant management of recipients undergoing liver transplantation for hepatocellular carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference.
    Transplantation. 2020 Mar 23. doi: 10.1097/TP.0000000000003196.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.